---
title: "ibrutinib_plus_bendamustine_and_rituximab_in_untreated_mantle-cell_lymphoma"
slug: "ibrutinibplusbendamustineandrituximabinuntreatedmantle-celllymphoma"
date: "2024-05-06"
enableToc: false
tags:
  - building
---

> [!info]
>
> üå± ‰æÜËá™Ôºö[[treatment-of-marginal_zone_lymphoma]]

# ibrutinib_plus_bendamustine_and_rituximab_in_untreated_mantle-cell_lymphoma

> Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine. 2022;386(26):2482-2494. doi:10.1056/nejmoa2201817

‚ú® SHINE trial: PFS ÊúâÂπ´Âä©Ôºå‰ΩÜ OS Ê≤íÂ∑ÆÔºÅ

1. Design:

- Trial phase: III
- Multi-center
- Randomized
- Open-label

2. Number of patients: 523
3. Patients characteristics: Patients **65 years of age** or older with untreated mantle-cell lymphoma
4. Agent:
   - Intervention: Ibrutinib (560 mg, orally once daily) in combination with bendamustine (90 mg per square meter) and rituximab (375 mg per square meter)
   - Control: Placebo in combination with bendamustine and rituximab
5. Treatment line: First-line therapy
6. Trial Acronym or NCTId Number: NCT01776840
7. Comparison of outcomes:

| Outcome                         | Ibrutinib Group         | Placebo Group           |
| ------------------------------- | ----------------------- | ----------------------- |
| Progression-free survival (PFS) | 80.6 months             | 52.9 months             |
| Overall survival (OS)           | 55.0% at 7 years        | 56.8% at 7 years        |
| Response rate (RR)              | 65.5% Complete Response | 57.6% Complete Response |
